Breaking Canadian GLP-1 news
GLP-1 News — Page 6
Drug approvals, price changes, generic timelines, and clinical trial results affecting GLP-1 medication costs in Canada.
Where are you in your GLP-1 journey?
Answer a few quick questions — get your cheapest path to a GLP-1 prescription, free.
Novo Nordisk Eyes Third Generic as 65% Price-Cut Trigger Looms
Novo Nordisk executive Emil Kongshøj Larsen says a third generic semaglutide entry in Canada will trigger a mandated 65% cut to Novo's list price.
Generic Semaglutide Hits Tier 2 Pricing: ~$114 Per 4-Week Supply
With two generic semaglutide approvals in Canada, pCPA tier rules cap the public-plan price at roughly $114 per four-week supply, skipping Tier 1 entirely.
Health Canada Advisory: Counterfeit GLP-1 Products Found in Canada
Health Canada warns consumers about unauthorized and counterfeit GLP-1 products sold by retailers and online, and is working with CBSA to block shipments.
Alberta Blue Cross: GLP-1 Plan Spend Won't Drop Despite Generics
Alberta Blue Cross's 2026 pipeline report says GLP-1 plan spend is unlikely to decline even as a semaglutide generic arrives mid-2026, citing broader uses.
CDA Pegs Mounjaro Public Coverage at $1.97B Over Three Years
Canada's Drug Agency estimates public plans would spend $1.97 billion on Mounjaro over three years, about $820 million more than current comparable drug spending.
Health Canada: Many Generics Run 45-90% Below Brand Prices
Health Canada says many generic medications cost 45 to 90 per cent less than brand-name versions, a benchmark now in focus after two semaglutide approvals.
BMO Analyst: Canada Is 'Test Case' for Generic GLP-1 Competition
BMO Capital Markets analyst Evan Seigerman says investors will watch Canada closely to see whether generic semaglutide can compete with branded peptides.
Gerstein: GLP-1s Are 'Powerful Drugs,' Not Supplements
Hamilton diabetes researcher Dr. Hertzel Gerstein cautions Canadians that semaglutide is a powerful drug, not a supplement, as the second generic clears Health Canada.
Sockalingam: Under 20% of Private Plans Cover Obesity Drugs
Obesity Canada's Dr. Sanjeev Sockalingam says fewer than 20% of Canadians with private drug plans can access approved obesity medications, citing $27.6B in 2023 costs.
Second Generic Semaglutide Cleared; 7 Submissions Still Pending
Health Canada authorized Apotex's generic semaglutide May 1, 2026, the second G7-first approval, with seven more generic submissions still under review.
Health Canada Queue: 7 Semaglutide Generics Await Decisions
After authorizing a second generic semaglutide on May 1, Health Canada says seven more submissions remain under review with decisions due in coming weeks.
Novo Nordisk Sees 'Low Single-Digit' Hit from Canadian Generics
Novo Nordisk executive Emil Kongshøj Larsen told analysts the company expects only a low single-digit impact from generic semaglutide entering Canada.
Experts Welcome Generic Semaglutide, Urge Caution on Reliance
McGill's Dr. Kaberi Dasgupta and Obesity Canada's Ian Patton react to Health Canada's G7-first generic semaglutide approvals, citing equity gains and public-health risks.
Obesity Canada: Generic Semaglutide Approval Should Reshape Coverage
Obesity Canada says Health Canada's generic semaglutide approvals should prompt governments and insurers to revisit coverage, citing under-20% private plan access.
Health Canada Confirms G7-First Status After Apotex Generic Nod
Health Canada confirms G7-first generic semaglutide status after authorizing Apotex's version, with seven additional submissions still under active review.
Generic Semaglutide Pipeline: 7 Submissions Still Under Review
Health Canada confirms seven generic semaglutide submissions remain under review after the second approval on May 1, 2026, with more decisions expected.
Ozempic Topped Canadian Drug Sales at $2.9B in 2025: IQVIA
Ozempic was Canada's best-selling drug in 2025 with $2.9B in sales, more than triple the next-ranked medication, IQVIA data shows as generics arrive.
Apotex Won't Manufacture Generic Semaglutide in Canada
Apotex president Martin Arès confirms generic semaglutide pens won't be made at Canadian facilities, citing specialized manufacturing requirements.
Apotex Wins Health Canada Nod for 2nd Generic Semaglutide
Health Canada authorized Apotex's generic semaglutide injection on May 1, 2026, the second generic of Ozempic approved in the G7, with 7 more submissions in review.
Health Canada Reviewing 8 More Generic Semaglutide Submissions
Health Canada says decisions on 8 remaining generic semaglutide submissions are expected in coming weeks and months after Dr. Reddy's first approval.
Looking for current pharmacy prices?
Compare GLP-1 prices across Canada